The report "Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Service (Vector, Library Construction, Screening), Technique (Knock-Out), Technology (CRISPR, ZFN, RNAi, TALEN), Application, End User, Region, Competition - Global Forecast to 2031" is projected to reach USD 8.49 billion by 2031, up from USD 5.23 billion in 2026, at a CAGR of 10.1% during the forecast period.
Browse 631 market data Tables and 55 Figures spread through 453 Pages and in-depth TOC on "Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Service (Vector, Library Construction, Screening), Technique (Knock-Out), Technology (CRISPR, ZFN, RNAi, TALEN), Application, End User, Region, Competition - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/genome-editing-engineering-market-231037000.html
The global gene editing market is growing rapidly, driven by advances in CRISPR-based genome editing, rising investment in genetic research, and increasing adoption of precision medicine. Growing applications of gene editing in drug discovery and development, expanding research on genetic disorders, and rising demand for genetically engineered cell lines further support market expansion.
The reagents & consumables segment accounted for the largest share of the global gene editing products market, by product, in 2025.
Based on product, the gene editing products market is segmented into reagents & consumables and software & systems. The reagents & consumables segment accounted for the largest share of the market in 2025, at 74.0%, driven by recurring demand for gene editing kits, screening libraries, guide RNAs, nucleases, and other consumables required for genetic modification. Growing applications in drug discovery, cell line engineering, and functional genomics, along with rising demand for efficient genome-editing workflows, support the segment's leading position.
The library construction & screening segment is estimated to be the fastest-growing service type segment in the gene editing services market.
The global gene editing services market is segmented by service type into cell line development & characterization, gRNA synthesis & vector construction, library construction & screening, and other services. During the forecast period, the library construction & screening segment is expected to grow strongly, driven by increasing adoption of high-throughput CRISPR screening, expanding functional genomics research, and rising demand for drug target identification. The growing outsourcing of complex screening projects, advances in pooled and arrayed screening technologies, and rising pharmaceutical research activity are expected to accelerate adoption of these services.
North America accounted for the largest regional share of the global gene editing market in 2025.
The gene editing market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2025, North America accounted for the largest share of the gene editing market, driven by strong pharmaceutical and biotechnology activity, advanced research infrastructure, and widespread adoption of CRISPR-based technologies. The region benefits from substantial investment in genetic research, precision medicine, and drug discovery, along with leading gene editing product manufacturers and specialized service providers. Increasing applications of gene editing in cell line engineering, functional genomics, and therapeutic development, supported by collaborations between research institutions, pharmaceutical companies, and biotechnology organizations, further strengthen the region's market position.
Key players in the gene editing market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript Biotech Corporation (China), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Lonza Group AG (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics, Inc. (US), Precision BioSciences, Inc. (US), Cellectis S.A. (France), Regeneron Pharmaceuticals, Inc. (US), AMSBIO (UK), Creative Biogene (US), Synthego Corporation (US), Takara Bio Inc. (Japan), Bio-Techne Corporation (US), Caribou Biosciences, Inc. (US), Bioneer Corporation (South Korea), REPROCELL Incorporated (Japan), and Alstem Cell Advancements (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com